Sanara MedTech Inc. (SMTI) Stock Score, Valuation & Financial Research
Sanara MedTech Inc. is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 19/100.
Quick answer for SMTI
Sanara MedTech Inc. currently has a Wall Street Score of 19/100. The stored market price is $34.92. Its financial score is 15/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Sanara MedTech Inc. does
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation
SMTI financial snapshot
- Wall Street Score:
- 19/100
- Current price:
- $34.92
- Market capitalization:
- $321.0M
- Revenue:
- $107.5M
- Net income:
- $-33.6M
- Free cash flow:
- $2.2M
- Cash:
- $13.6M
- Total debt:
- $48.4M
- EPS:
- -4.36
- Financial score:
- 15/100
- Valuation score:
- 0/100
- Revenue score:
- 29/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $2.2M, showing positive cash generation.
- The balance sheet shows $13.6M of cash versus $48.4M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 15/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research SMTI
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.